Gilead Sciences Inks US$750 M Deal with Kymera Therapeutics for Novel Oral Molecular Glue CDK2 Degraders
By Naini Anand
Pharma Deals Review: Vol 2025 Issue 7 (Table of Contents)
Published: 21 Jul-2025
DOI: 10.3833/pdr.v2025.i7.2959 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Gilead Sciences has entered into a strategic licensing agreement with Kymera Therapeutics to accelerate the development of a novel molecular glue degrader (MGD) programme targeting cyclin-dependent kinase 2 (CDK2), a protein implicated in tumour growth, for the treatment of breast cancer and other solid tumours...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS